Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683369 · ClinicalTrials.gov registry record · Phase 2
Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02683369: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT02683369 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683369, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. The investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses of iron supplementation.
Primary Outcome
Marker of iron status
Interventions
- DIETARY_SUPPLEMENT Blood Builder®/Iron Response®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
What the finished NCT02683369 record still lists
NCT02683369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Blood Builder®/Iron Response® is the first listed.
NCT02683369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02683369 about?
NCT02683369 is a clinical study titled "Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women". Healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. The investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses ...
What is the current status of trial NCT02683369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2016-02. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02683369?
The interventions under investigation include: Blood Builder®/Iron Response® (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02683369?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02683369's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia